Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Hamburg - Delayed Quote EUR

BioNTech SE (22UA.HM)

Compare

114.30

+2.10

+(1.87%)

As of 5:25:12 PM GMT+1. Market Open.

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?

Here is how Auna S.A. (AUNA) and BioNTech SE Sponsored ADR (BNTX) have performed compared to their sector so far this year.

Zacks 7 days ago

AUNA

BNTX
What Makes BioNTech (BNTX) a New Buy Stock

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 8 days ago

BNTX
Oncology vaccine trial sees all patients living kidney cancer-free

Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping cancer.

Clinical Trials Arena 15 days ago

BNTX
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

RFK Jr. cleared a key hurdle Tuesday after the Senate Finance Committee voted along party lines to send his nomination to the full chamber.

Investor's Business Daily 16 days ago

BNTX

PFE

GLAXF
Health, pharma stocks fall as RFK Jr. clears crucial vote

Health and pharmaceutical stocks — including Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX) — are under pressure on Tuesday after Robert F. Kennedy Jr. passed the Senate Finance Committee's vote on the Department of Health and Human Services (HHS) Secretary nominee. His nomination will now proceed to a full Senate vote. Wealth anchor Brad Smith is joined by Seana Smith in analyzing the market reaction, exploring several of Kennedy Jr.'s controversial views on healthcare issues, particularly vaccines. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Angel Smith

Yahoo Finance Video 17 days ago

MRNA

BNTX

NVAX
MHRA seeks input on new regulatory guidance for cancer vaccines

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

Pharmaceutical Technology 17 days ago

BNTX
BioNTech Completes Acquisition of Biotheus

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodiesBiotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufact

GlobeNewswire 18 days ago

BNTX
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Investor's Business Daily 27 days ago

BNTX

PFE

NVAX
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection

How expensive is the stock market right now? BioNTech (NASDAQ: BNTX) vaulted into the spotlight in 2020 when Pfizer teamed up with the then-small German company to develop a COVID-19 vaccine. Today, BioNTech is much larger with a market cap of around $27 billion.

Motley Fool 30 days ago

BNTX

^GSPC

ET
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

BNTX
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology (“IO”) backbone for the Company’s combination strategy targeting a broad range of indicationsProgressing development of BNT327/PM8002 with initiation of global clinical trials with registrational potential in first-line small cell lung cancer (“SCLC”) and non-small cell lung can

GlobeNewswire last month

BNTX
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

On Thursday, Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc (NYSE:PFE). BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development and upcoming catalysts. The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023. Als

Benzinga last month

BNTX
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Investor's Business Daily last month

MRNA

BNTX

NVAX
Private equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as well

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more power...

Simply Wall St. last month

BNTX
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.

For pharmaceutical stocks, there are few events as crucial as the results of clinical trials for new drugs.

Barrons.com last month

LLY

PFE

NVO
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania regarding past and future royalties on the company and partner Pfizer’s (PFE) COVID vaccine, Comirnaty. Noting that the deal will result in two low-single digit percentage royalties on forward sales of Comirnaty and the companies will pay $1.15B for historical royalties, the firm says it views this as

TipRanks last month

PFE

BNTX
BioNTech to pay $467M in settlement agreement with University of Pennsylvania

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University of Pennsylvania concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its collaboration partner, Pfizer’s (PFE) COVID-19 vaccine since commercialization. On December 23, 2024, the Company entered into a binding term sheet with Penn to provide terms on which the Company retains license rights under certain Penn patent rights in order to

TipRanks last month

BNTX

PFE
BioNTech to pay $791.5M in settlement agreement with the NIH

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the National Institutes of Health concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its collaboration partner, Pfizer’s (PFE) COVID-19 vaccine since commercialization. On December 20, 2024, the Company entered into a settlement agreement with the NIH. Under the terms of the Settlement Agreement, the Company will, among other things, pay $791.5M,

TipRanks last month

BNTX

PFE
BioNTech Settles Royalty Dispute with NIH for $791.5 Million

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, developed in collaboration with Pfizer. The settlement involves a payment of $791.5 million to the NIH, resolving past claims and adjusting future royalty arrangements. The settlement does not imply any admission of liability by BioNTech, and Pfizer has agreed to reimburse $364.5 million of the settlemen

TipRanks last month

BNTX
BioNTech Settles Royalty Dispute with University of Pennsylvania

The latest update is out from BioNTech SE ( (BNTX) ). BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn, which includes royalties for past sales and funding for extended research collaboration. Pfizer has also agreed to reimburse BioNTech for part of these royalties. More about BioNTech SE BioNTech SE is a

TipRanks last month

BNTX

Performance Overview

Return	22UA.HM	MSCI WORLD
YTD	+5.06%	+3.98%
1-Year	+34.25%	+17.82%
3-Year	-15.44%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNTech SE (22UA.HM)

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?

What Makes BioNTech (BNTX) a New Buy Stock

Oncology vaccine trial sees all patients living kidney cancer-free

RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.

Health, pharma stocks fall as RFK Jr. clears crucial vote

MHRA seeks input on new regulatory guidance for cancer vaccines

BioNTech Completes Acquisition of Biotheus

Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots

3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection

Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know

BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Private equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as well

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.

NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley

BioNTech to pay $467M in settlement agreement with University of Pennsylvania

BioNTech to pay $791.5M in settlement agreement with the NIH

BioNTech Settles Royalty Dispute with NIH for $791.5 Million

BioNTech Settles Royalty Dispute with University of Pennsylvania

Performance Overview